Oric Pharmaceuticals (NASDAQ:ORIC) Shares Gap Down After Analyst Downgrade

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) shares gapped down prior to trading on Wednesday after Wedbush lowered their price target on the stock from $20.00 to $17.00. The stock had previously closed at $12.67, but opened at $10.25. Wedbush currently has an outperform rating on the stock. Oric Pharmaceuticals shares last traded at $9.2510, with a volume of 2,218,391 shares trading hands.

Other equities analysts have also recently issued reports about the company. Wells Fargo & Company upped their price objective on Oric Pharmaceuticals from $19.00 to $25.00 and gave the stock an “overweight” rating in a report on Monday, December 8th. HC Wainwright reissued a “buy” rating and set a $25.00 price objective on shares of Oric Pharmaceuticals in a report on Friday, March 13th. Wall Street Zen upgraded Oric Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Oric Pharmaceuticals in a research note on Monday, March 9th. Finally, Citigroup increased their price target on shares of Oric Pharmaceuticals from $16.00 to $17.00 and gave the company a “buy” rating in a research report on Tuesday, February 24th. Eleven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $19.90.

Insider Transactions at Oric Pharmaceuticals

In other news, CFO Dominic Piscitelli sold 52,000 shares of the firm’s stock in a transaction dated Tuesday, February 24th. The stock was sold at an average price of $13.51, for a total transaction of $702,520.00. Following the transaction, the chief financial officer directly owned 68,148 shares of the company’s stock, valued at approximately $920,679.48. This trade represents a 43.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 6.82% of the stock is currently owned by insiders.

Oric Pharmaceuticals News Roundup

Here are the key news stories impacting Oric Pharmaceuticals this week:

• Positive Sentiment: Company selected rinzimetostat 400 mg once daily as the RP3D in combination with darolutamide and plans to start the Himalayas‑1 registrational Phase 3 in 1H 2026 — a clear clinical progress milestone that advances the program toward potential registration. ORIC Reports RP3D Selection (GlobeNewswire)
• Positive Sentiment: Press coverage highlights Oric moving into Phase 3 and positioning its candidate against competitors (e.g., Pfizer), which could increase program value if registrational endpoints are met. Oric chases Pfizer into phase 3 (FierceBiotech)
• Neutral Sentiment: Analyst reaction was mixed: Wedbush cut its price target from $20 to $17 but maintained an “outperform” rating, signaling continued institutional conviction despite the recent risk repricing. Wedbush price target update (Benzinga)
• Negative Sentiment: Investors dumped shares after the Phase 1b update revealed safety/tolerability issues at higher doses and side‑effect data that raised questions about the optimal therapeutic window, prompting an after‑hours drop and heavy intraday volume. ORIC drops after trial data (Seeking Alpha)
• Negative Sentiment: Mainstream reports emphasize safety/side‑effect concerns tied to the combo regimen and note the stock’s sharp fall, reinforcing negative investor sentiment in the short term. Shares fall on side-effect data (MarketWatch)

Hedge Funds Weigh In On Oric Pharmaceuticals

A number of large investors have recently bought and sold shares of the stock. Federation des caisses Desjardins du Quebec lifted its position in Oric Pharmaceuticals by 100.0% in the fourth quarter. Federation des caisses Desjardins du Quebec now owns 4,000 shares of the company’s stock valued at $33,000 after purchasing an additional 2,000 shares during the last quarter. Assetmark Inc. bought a new position in shares of Oric Pharmaceuticals in the third quarter worth approximately $37,000. Caitong International Asset Management Co. Ltd increased its stake in shares of Oric Pharmaceuticals by 184.4% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 4,528 shares of the company’s stock worth $37,000 after buying an additional 2,936 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Oric Pharmaceuticals by 26.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,732 shares of the company’s stock worth $39,000 after buying an additional 977 shares during the period. Finally, Russell Investments Group Ltd. bought a new stake in Oric Pharmaceuticals during the 3rd quarter valued at $60,000. 95.05% of the stock is owned by hedge funds and other institutional investors.

Oric Pharmaceuticals Trading Down 41.0%

The company has a market capitalization of $749.69 million, a P/E ratio of -4.91 and a beta of 1.36. The stock’s fifty day moving average is $11.62 and its 200 day moving average is $11.31.

Oric Pharmaceuticals (NASDAQ:ORIC) last announced its quarterly earnings results on Monday, February 23rd. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.04. On average, analysts expect that Oric Pharmaceuticals, Inc. will post -2.17 EPS for the current fiscal year.

About Oric Pharmaceuticals

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.